Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Recruiting

68-Ga-PSMA-11Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

Sponsor:

Telix Pharmaceuticals (Innovations) Pty Limited

Code:

NCT06655064

Conditions

Prostate Cancer (Adenocarcinoma)

Eligibility Criteria

Sex: Male

Age: 21+

Healthy Volunteers: Not accepted

Interventions

None- Observational

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Telix Pharmaceuticals (Innovations) Pty Limited on 2025-03-30.